The Management of Glioblastomas during the SARS-CoV-19 Pandemic: A Narrative Overview

Mohamed Amine Baba 1 2 * , Nawal Adali 1 2
More Detail
1 Laboratory of Health Sciences Research, Ibn Zohr University, 80000 Agadir, MOROCCO
2 Faculty of Medicine and Pharmacy of Agadir, Ibn Zohr University, 80000 Agadir, MOROCCO
* Corresponding Author
EUR J BASIC MED SCI, Volume 11, Issue 2, pp. 19-22.
Download Full Text (PDF)


The SARS-CoV-2 pandemic and covid-19 diffusion are an international public health emergency. Patients with a history of cancer have a higher incidence of infection with severe acute respiratory syndrome–coronavirus 2 (SARS-CoV-2) and higher risk of severe COVID-19–associated events.
Glioblastoma is considered to be among the most aggressive cancers,in this direction the value of treatment must be balanced with risks of exposure to infection, inducing immunosuppression and survival benefit.
the objective of this review is to present all international consensus recommendation for the management of patients with glioblastoma (GBM) to inform clinical practice.
During this pandemic crisis, careful patient selection that balances the risks and benefits of treatment is paramount to optimize the care of patients with glioblastoma in this setting.


Baba MA, Adali N. The Management of Glioblastomas during the SARS-CoV-19 Pandemic: A Narrative Overview. Eur J Basic Med Sci. 2021;11(2):19-22.


  • Guan W-J, Ni Z-Y, Hu Y, Liang W-H, et al. Clinical characteristics of coronavirus disease 2019 in China. N Engl J Med. 2020; 382(18): 1708-20. doi: 10.1056/NEJMoa2002032 PMid:32109013 PMCid: PMC7092819.
  • Liang W, Guan W, Chen R, Wang W, et al. Cancer patients in SARS-CoV-2 infection: A nationwide analysis in China. The Lancet. 2020; 21(3): 335-7. doi: 10.1016/S1470-2045(20)30096-6.
  • Liu K, Chen Y, Lin R, Han K. Clinical features of COVID-19 in elderly patients: A comparison with young and middle-aged patients. J Infect. 2020; 80(6): e14-e18. doi: 10.1016/j.jinf.2020.03.005 PMid:32171866 PMCid:PMC7102640.
  • Brooke J, Jackson D. Older people and COVID‐19: Isolation, risk and ageism. J Clin Nurs. 2020; 29(13-14): 2044-6. doi: 10.1111/jocn.15274 PMid: 32239784.
  • Stupp R, Mason WP, van den Bent MJ, Weller M, et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med. 2005; 352(10): 987-96. doi: 10.1056/NEJMoa043330 PMid:15758009.
  • Weller M, van den Bent M, Tonn JC, Stupp R, et al. European Association for Neuro-Oncology (EANO) guideline on the diagnosis and treatment of adult astrocytic and oligodendroglial gliomas. Lancet Oncol. 2017; 18(6): e315-e329. doi: 10.1016/S1470-2045(17)30194-8 PMID: 28483413.
  • Chaichana KL, Jusue-Torres I, Lemos AM, Gokaslan A, et al. The butterfly effect on glioblastoma: is volumetric extent of resection more effective than biopsy for these tumors? J Neurooncol. 2014; 120(3): 625-34. doi: 10.1007/s11060-014-1597-9 PMid:25193022 PMCid:PMC4313925.
  • Chaichana KL, Jusue-Torres I, Navarro-Ramirez R, Raza SM, et al. Establishing percent resection and residual volume thresholds affecting survival and recurrence for patients with newly diagnosed intracranial glioblastoma. Neuro Oncol. 2014; 16(1): 113-22. doi: 10.1093/neuonc/not137 PMid: 24285550 PMCid:PMC3870832.
  • Sanai N, Polley M-Y, McDermott MW, Parsa AT, Berger MS. An extent of resection threshold for newly diagnosed glioblastomas. J Neurosurg. 2011; 115(1): 3-8. doi: 10.3171/2011.2.jns10998 PMid: 21417701.
  • Senft C, Bink A, Franz K, Vatter H, et al. Intraoperative MRI guidance and extent of resection in glioma surgery: a randomised, controlled trial. Lancet Oncol. 2011; 12(11): 997-1003. doi: 10.1016/S1470-2045(11)70196-6
  • Bernhardt D, Wick W, Weiss SE, Sahgal A, et al. Neuro-oncology Management During the COVID-19 Pandemic with a Focus on WHO Grade III and IV Gliomas. Neuro-Oncol. 2020; 22(7): 928-35. doi: 10.1093/neuonc/noaa113 PMid:32369601 PMCid: PMC7239150.
  • Núñez-Velasco S, Mercado-Pimentel R, Rodríguez-Arias R. Letter to the Editor: Awake Craniotomy for Intracranial Gliomas During Coronavirus Disease 2019 Pandemic. World Neurosurg. 2020; 140: 470-2. doi: 10.1016/j.wneu.2020.05.219 PMid: 32485243 PMCid:PMC7260566.
  • Chen Z-P. Glioma patients facing COVID-19 pandemic. Glioma. 2020; 3(1): 1. doi: 10.4103/glioma.glioma_6_20
  • Ramakrishna R, et al. Inpatient and outpatient case prioritization for patients with neuro-oncologic disease amid the COVID-19 pandemic: general guidance for neuro-oncology practitioners from the AANS/CNS Tumor Section and Society for Neuro-Oncology. J Neurooncol. 2020; 147(3): 525-9. doi: 10.1007/s11060-020-03488-7 PMid: 32274630 PMCid:PMC7145274.
  • Wu S, Zheng D, Liu Y, Hu D, et al. Radiation Therapy Care During a Major Outbreak of COVID-19 in Wuhan. Adv Rad Oncol. 2020; 5(4): 531-3. doi: 10.1016/j.adro.2020.03.004 PMid:32775770 PMCid:PMC7270882.
  • Hegi ME, Diserens A-C, Gorlia T, Hamou M-F, et al. MGMT gene silencing and benefit from temozolomide in glioblastoma. N Engl J Med. 2005; 352(10): 997-1003. doi: 10.1056/NEJMoa043331 PMid:15758010.
  • Al-Jabir A, et al. Impact of the coronavirus (COVID-19) pandemic on surgical practice-Part 2 (surgical prioritisation). Int J Surg. 2020; 79: 233-48. doi: 10.1016/j.ijsu.2020.05.002 PMid:32413502 PMCid: PMC7217115.
  • Baba MA, et al. Risk of COVID-19 for Patients with Cancer: A Narrative Overview. European J Med Ed Te. 2020; 13(3): em2008. doi: 10.30935/ejmets/8257.